180 related articles for article (PubMed ID: 11383110)
1. Closing in on cancer.
Park A
Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
[No Abstract] [Full Text] [Related]
2. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
3. Angiogenesis. A boost for tumor starvation.
Marx J
Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
[No Abstract] [Full Text] [Related]
4. Novel agents target existing tumor vasculature.
Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
[No Abstract] [Full Text] [Related]
5. Therapeutic targeting of the tumor vasculature.
Tozer GM; Bicknell R
Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenic mechanisms in cancer].
Bjerkvig R
Tidsskr Nor Laegeforen; 2000 Nov; 120(29):3501. PubMed ID: 11188372
[No Abstract] [Full Text] [Related]
7. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
Ellis LM
J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
[No Abstract] [Full Text] [Related]
8. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
9. [Angiogenesis in cancer].
Pozner RG; Negrotto S; Schattner M
Medicina (B Aires); 2002; 62(6):604-6. PubMed ID: 12532700
[No Abstract] [Full Text] [Related]
10. Endogenous inhibitors of angiogenesis.
Folkman J
Harvey Lect; 1996-1997; 92():65-82. PubMed ID: 15372744
[No Abstract] [Full Text] [Related]
11. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
Gagne P; Akalu A; Brooks PC
Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
[TBL] [Abstract][Full Text] [Related]
12. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
13. Cancer research. Obstacle for promising cancer therapy.
Marx J
Science; 2002 Feb; 295(5559):1444. PubMed ID: 11859164
[No Abstract] [Full Text] [Related]
14. The fight against cancer: the next round.
Doherty M
Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
[No Abstract] [Full Text] [Related]
15. Angiogenesis research: guidelines for translation to clinical application.
Folkman J; Browder T; Palmblad J
Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
[TBL] [Abstract][Full Text] [Related]
16. Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon LH
J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
[No Abstract] [Full Text] [Related]
17. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
18. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
d'Onofrio A; Gandolfi A
Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
[TBL] [Abstract][Full Text] [Related]
19. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]